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Inflammation disrupts tissue architecture and function, thereby
contributing to the pathogenesis of diverse diseases; the signals
that promote or restrict tissue inflammation thus represent poten-
tial targets for therapeutic intervention. Here, we report that
genetic or pharmacologic Hedgehog pathway inhibition intensifies
colon inflammation (colitis) in mice. Conversely, genetic augmenta-
tion of Hedgehog response and systemic small-molecule Hedgehog
pathway activation potently ameliorate colitis and restrain initiation
and progression of colitis-induced adenocarcinoma. Within the
colon, the Hedgehog protein signal does not act directly on the
epithelium itself, but on underlying stromal cells to induce expres-
sion of IL-10, an immune-modulatory cytokine long known to
suppress inflammatory intestinal damage. IL-10 function is required
for the full protective effect of small-molecule Hedgehog pathway
activation in colitis; this pharmacologic augmentation of Hedgehog
pathway activity and stromal IL-10 expression are associated with
increased presence of CD4+Foxp3+ regulatory T cells. We thus iden-
tify stromal cells as cellular coordinators of colon inflammation and
suggest their pharmacologic manipulation as a potential means to
treat colitis.
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Human inflammatory bowel disease (IBD) comprises twomajor disease subtypes, Crohn’s disease (CD) and ulcerative
colitis (UC), each associated with considerable morbidity and
mortality. Genetic studies of IBD patients have uncovered loss-
of-function mutations affecting IL-10 or its receptor (1, 2), but
the cells and additional signaling interactions controlling in-
flammation remain to be fully defined. Genome-wide association
studies of IBD patients have identified genes associated with
CD and/or UC risk (3), as exemplified by a naturally occurring
polymorphism in the coding region of the GLI1 gene, which
is associated with a significant predisposition to UC in Northern
Europeans (4). GLI1 encodes a transcriptional effector of Hedge-
hog (Hh) signaling whose genetic loss in mice causes a partial
impairment of Hh response that is nonetheless compatible with
development and fertility (5, 6); the increased risk of UC in asso-
ciation with GLI1 alteration suggests a potential involvement of
Hh signaling in colon inflammation.
Results
Reduction of Hh Pathway Activity Exacerbates Acute DSS-Induced
Colitis. To investigate the role of Hh signaling in IBD, we
first tested whether Gli1 inactivation increases the severity of
acute dextran sulfate sodium (DSS)-induced colitis in mice
(7). We obtained inconclusive results, quite distinct from those
previously reported (Fig. S1) (4), possibly because of differences
in housing, the genetic background, or the microbiota of the mice
used in the two studies. However, Gli1 loss only partially impairs
Hh response (5), leaving open the possibility of a more striking
effect with more severe impairment.
To definitively ablate Hh signaling in the colon, we deleted the
essential Hh transduction component Smoothened (8). Response
to Hh signaling in colon is restricted to stromal cells, as indicated
by the expression of Gli1 (Fig. 1 B and C), which is not only a
mediator but also a target of Hh signaling (5, 9). Stromal abla-
tion of Smo (in a Smofl/fl background) thus can be accomplished
using the stromally activeGli1CreER driver (10) in the presence of
tamoxifen to activate CreER recombinase. Indeed, tamoxifen
treatment of Gli1CreER/+;Smofl/fl mice produced a 4.5-fold re-
duction in Gli1 transcript levels by quantitative RT-PCR (qRT-
PCR) analysis compared with Gli1CreER/+;Smoflox/+ control mice
(Fig. S2A).
We found that, in these Smo-ablated mice, a light regimen
of DSS exposure [2.5% (wt/vol) for 5 d, with scarcely any
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effect on wild type] sufficed to reliably induce weight loss
(Fig. 1D) as well as a significant increase in the mean colitis
severity score (from 0.9 to 2.7; Fig. 1E), as determined histo-
logically by a pathologist (E.S.S.) blinded to the genetic back-
ground and treatment regimen of the mice (Fig. 1H; Materials
and Methods). Complementing these genetic results, we found
that pharmacologic inhibition of Hh response using the small-
molecule Hh pathway antagonist XL-139 (11, 12) (Fig. S2B) also
significantly accelerated weight loss (Fig. 1F) and increased the
severity of colitis (from a score of 0.3 to 2.3; Fig. 1G). In sum-
mary, both genetic and pharmacologic manipulations that deci-
sively block Hh response enhanced the development of colitis
at levels of DSS exposure that scarcely produced any effect in
mice with intact Hh response. The marked effect of selective
Smo ablation by Gli1CreER moreover shows that Gli1-expressing
stromal cells are the critical target for colitis enhancement by
Hh antagonism.
Elevated Hh Pathway Activity Decreases Acute DSS-Induced Colitis.
As reduced Hh response exacerbates acute DSS colitis, we
considered the possibility that genetic or pharmacological acti-
vation of Hh signaling might ameliorate colitis. Indeed, we found
that Hh signaling, although normally active at moderate levels in
uninjured colon (as evidenced by expression of Hh target genes
Ptch1 and Hhip), is significantly suppressed during DSS-induced
colitis (Fig. S3A: Vehicle–No Injury vs. Vehicle–DSS). To test
whether Hh pathway activation could ameliorate colitis, we first
examined colitis severity in mice with a slight general elevation of
Hh activity caused by heterozygous mutation of Ptch1 (13) (Fig.
2A), which was backcrossed over 10 generations into an FVB
background to permit comparison with FVB wild-type mice.
These Ptch1+/− heterozygous mice developed significantly less
severe DSS-induced colitis (severity score of 1.8 vs. 3.4; Fig. 2B)
and showed decreased colitis-associated mortality (91% vs. 55%
survival; Fig. 2C).
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Fig. 1. Decreased Hh pathway response exacerbates acute DSS-induced colitis. (A) Overview of acute DSS-induced colitis experiments. T indicates days of
tamoxifen treatment, arrowheads indicate the day of colon harvest, and colored bars indicate the duration of DSS exposure and XL-139 treatment.
(B) Confocal image shows the stromal localization of Gli1-expressing cells using an antibody that detects nuclear expression of β-galactosidase in a Gli1LacZ/+
mouse. Epithelial cells are detected with an anti-Epcam antibody. (C) Confocal image of a colon section from a tamoxifen-treated Gli1CreER/+;R26mTmG/+mouse
shows Gli1-expressing cells, as marked by expression of membrane-associated GFP, in the lamina propria closely juxtaposed to colon crypt epithelial cells (anti-
Epcam antibody). (D and E) Gli1CreER/+;Smofl/fl animals vs. Gli1CreER/+;Smofl/+ controls showed a greater loss of total body weight [(D) day 10, 83.8% vs. 97.9%
original body weight, *P < 0.0001] and more severe colitis by histologic grading [(E) 2.7 vs. 0.9, *P = 0.0004; see H]. (F and G) XL-139–treated animals vs.
vehicle-treated controls showed a greater loss of total body weight [(F) day 10, 90.5% vs. 112.1% original body weight, *P < 0.0001] and more severe colitis
[(G) day 10, 2.3 vs. 0.3 severity score, *P < 0.0001]. (H) Representative H&E-stained cross-sections of distal colons from acute-DSS colitis experiments showing
varying levels of colitis severity, as discussed in the text (Materials and Methods).
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To further explore pathway activation, we tested the effect of a
small-molecule Smoothened agonist, SAG21k (14, 15), which
generates a 2.8-fold maximal elevation of Gli1 transcript levels in
the colon of uninjured FVB mice at a dose of 0.5 mg/kg twice per
day (Fig. S2D). The relatively modest degree of Gli1 induction by
SAG21k in uninjured colon compared with vehicle likely is due to
constitutive expression of Hh ligands in the epithelium, which
generates a fairly high basal level of stromal Gli1 expression (16–
18) (Fig. 1 B and C). In the setting of colitis-induced reduction of
Hh pathway activity (Fig. S3A), SAG21k treatment induced a
return of Hh pathway target expression to levels like those in
uninjured mice treated with SAG21k (Fig. S3A: SAG21k–No In-
jury vs. SAG21k–DSS), thus resulting in a strong relative induction
of Hh targets (e.g., a 16.0-fold change in Gli1, Fig. 2D; Fig. S3A).
Having established that SAG21k treatment causes a major and
highly significant change in the level of Hh pathway activity in
the setting of DSS-induced colitis, we examined the effects of
SAG21k treatment on colitis severity when applied either before
or after the initiation of DSS injury. First, either vehicle or
SAG21k was given to mice beginning 5 d before exposure to a
severe colitis-inducing regimen [5% (wt/vol) DSS for 5 d; Fig.
2A]. In this setting, colitis severity was greatly reduced in the
SAG21k group compared with the vehicle controls (severity
score of 0.6 vs. 4.8; Fig. 2 E and G). Second, mice were given
either vehicle or SAG21k starting 4 d after the start of DSS
treatment with a milder colitis-inducing regimen [2% (wt/vol)
DSS for 7 d; Fig. 2A]. SAG21k-treated mice showed less severe
colitis at day 7 compared with vehicle-treated controls (severity
score of 1.9 vs. 3.1; Fig. 2F). Thus, increased Hh pathway activity,
achieved genetically (in Ptch1+/− mice) or pharmacologically (by
SAG21k administration), has a strong protective effect in DSS-
induced colitis. Furthermore, pharmacologic Hh pathway acti-
vation can ameliorate colitis when applied either before or after
the start of DSS injury.
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Fig. 2. Increased Hh pathway response ameliorates acute DSS-induced colitis. (A) Overview of experiments. Arrowheads indicate day of colon harvest.
Colored bars indicate the duration of DSS exposure. Dots indicate the timing of either vehicle or SAG21k doses. (B) Ptch1+/− animals show less severe colitis
than Ptch1+/+ controls (average severity scores, 1.8 vs. 3.4; *P = 0.0104). (C) Survival is increased in Ptch1+/− vs. Ptch1+/+ animals following a 7-d period of DSS
injury (90.9% vs. 54.5% survival, *P = 0.0449, log-rank test). (D) Microarray heat map shows induction of Hh pathway targets in SAG21k (n = 3)- vs. vehicle (n =
3)-treated mice during DSS injury. Comparison of expression levels in the two treatment groups reveals the following t test P values: Hhip, 0.003; Igf1, 0.001;
Gli1, 8.3 × 10−6; Ptch1, 0.004; and Myocd, 0.027. (E) SAG21k-treated FVB mice display less severe colitis than vehicle-treated FVB controls (average severity
score, 0.62 vs. 4.75; *P < 0.0001). (F) C57BL/6 mice treated with SAG21k showed less severe colitis than vehicle-treated controls by histologic grading at day 7
(average severity score, 1.9 vs. 3.1; *P = 0.0197). SAG21k or vehicle treatment was started on day 4. (G) Representative H&E stains of distal colon show less
severe colitis in SAG21k-treated mice (Right) compared with vehicle-treated mice (Left), from the experiment in E.
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The Colitis-Protective Effect of Hh Pathway Activity Is Mediated in
Part by Increased IL-10 Expression in Gli1+ Stromal Cells. Given that
Hh pathway activation suppresses colitis, we sought to identify
the cellular locus of pathway activity. Interestingly, although
colitis is viewed primarily as an inflammatory disease, we found
no evidence by immunofluorescence staining (Fig. S4A) or by
FACS analysis (Fig. S4B) of pathway activity in hematopoietic
cells of injured or uninjured colon, as indicated by absence of
Gli1 coexpression with the general hematopoietic marker,
CD45; this nonoverlap of Gli1 expression with CD45 was con-
firmed by nonoverlap with markers of subpopulations of he-
matopoietic cells (CD11b, CD11c, F4/80, or CD206, in Fig. S5
C–L). Given this absence of Gli1 expression in hematopoietic
cells of the colon, we focused directly on Gli1-expressing (Gli1+)
colon stromal cells to identify factors that might mediate the
protective effect of Hh response. To this end, we subjected
FACS-isolated Gli1+ cells from the colons of SAG21k- and
vehicle-treated mice (Fig. 3 A and B) to microarray analysis, and
noted the expected induction by SAG21k of Hh pathway targets,
including Hhip, Igf1, Myocd, Gli1, and Ptch1 (Fig. 3C). Notably,
we also observed a threefold induction in IL-10 expression
levels, confirmed as a 6.3-fold induction by qRT-PCR (Fig. 3D).
In the setting of DSS-induced colitis (Fig. 3A), SAG21k induction
of IL-10 was even more dramatic in Gli1+ colon stromal cells (Fig.
3E), and this induction was not observed in FACS-isolated he-
matopoietic or epithelial cell populations from the colons of DSS-
exposed animals (Fig. 3F; FACS plots shown in bottom two panels
of Fig. S4B).
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Fig. 3. The protective effect of Hh response in colitis is mediated in part by increased IL-10 expression. (A) Overview of experiments. Tamoxifen treatment (T),
colon harvest (arrowheads), duration of DSS exposure (blue bars), and vehicle or SAG21k doses (dots) are shown. (B) FACS plots showing the isolation of Hh-
responsive GFP+ marked cells (boxed, Right, in each plot) from colons of Gli1CreER/+;R26mTmG/+ mice that were given tamoxifen, then treated with vehicle or
SAG21k (as schematized in A, top diagram;Materials and Methods). (C) Microarray heat map shows induction of Hh pathway targets as well as IL-10 in FACS-
purified Gli1+ (GFP+) cells from SAG21k (n = 3)- vs. vehicle (n = 3)-treated Gli1CreER/+;R26mTmG/+ mice. Comparison of expression levels in the two treatment
groups yielded the following t test P values: Hhip, 0.039; Igf1, 0.088; Myocd, 0.049; Gli1, 0.058; Ptch1, 0.049; and IL-10, 0.009. (D) IL-10 mRNA expression was
6.3-fold higher in FACS-purified GFP+ cells from noninjured mice given SAG21k vs. vehicle. (E and F) IL-10 expression in FACS-purified cell populations from
DSS-injured mice given either vehicle or SAG21k is shown. ND indicates no detection after 40 cycles of amplification. (G) The colitis-reducing effect of SAG21k
was decreased in IL-10−/−mice (1.3-unit change in mean severity score; P = 0.0101) compared with wild-type C57BL/6 mice (4.0-unit change; P < 0.0001). IL-10−/−
mice that did not receive DSS displayed a low background level of colitis (mean severity score, 1.0).
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The antiinflammatory role of the IL-10 cytokine in IBD has
long been known, with inactivating mutations in IL-10 or its
receptor causally linked to IBD in humans and mice (1, 2, 19–
21). To determine whether IL-10 expression indeed mediates the
protective effect of Hh stromal response, we exposed IL-10
mutant mice (IL-10−/−) to DSS and treated with SAG21k. The
IL-10−/− strain (1), on a C57BL/6 background, is known to de-
velop spontaneous colitis, which varies in severity depending on
housing conditions: we indeed noted a low-grade colitis (average
severity score, 1.0) without DSS exposure in our colony (Fig.
3G). These IL-10−/− mice were subjected to a 5-d exposure to
5% (wt/vol) DSS, which increased the average colitis severity
score to the maximum level of 5.0 in vehicle-treated mice (Fig.
3G). This severity score was reduced to an average of 3.7 in the
SAG21k treatment cohort (P = 0.01). The comparison vehicle-
treated wild-type group, also C57BL/6, developed an average
colitis severity score of 4.2 with DSS exposure, with a dramatic
reduction to 0.2 upon SAG21k treatment (P < 0.0001). We
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Fig. 4. Foxp3+ Treg levels in the colon are increased by Hh response as well as colitis. (A) Overview of experiments. Arrowheads indicate day of colon harvest.
Colored bars indicate duration of DSS. Dots indicate drug doses. (B) The percentage of Foxp3+ cells within the CD4+ population increases during DSS injury
[n = 8 mice (day 0), n = 4 (other time points)]. Mean percentage of Foxp3+/CD4+ cells was 9.9 on day 0 vs. 45.8 on day 10 (P < 0.0001). (C) Representative flow
plots (gated on CD4+ cells) show greatly increased percentage of Foxp3+ cells at day 10 vs. day 0 of DSS injury. (D) Mean percentage of Foxp3+/CD4+ cells
sharply increases at 1 d following SAG21k treatment (9.9, day 0, vs. 21.3, day 1; P = 0.0011). Afterward, Foxp3+ cells remain elevated through day 10 [n = 8
mice (day 0); n = 4 (other time points)]. (E) Representative flow plots show increased Foxp3+ cells at day 1 following SAG21k treatment compared with day
0 baseline levels. (F) After a 10-d DSS injury protocol, the percentage of CD4+Foxp3+ Treg cells increase dramatically in vehicle-treated mice. However, mice
treated with SAG21k had a decreased percentage of CD4+ Foxp3+ Treg cells vs. vehicle controls. (G–I) When a short course of SAG21k or vehicle was given
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conclude from these data that, although SAG21k can partially
reduce colitis in the absence of IL-10, induction of IL-10 ex-
pression is required and constitutes the major mechanism by
which Hh pathway activity suppresses colitis.
Hh Pathway Stimulation Increases the Amount of Foxp3+ Regulatory
T Cells in the Colon During Early DSS Injury. IL-10 suppresses colitis
by acting to maintain expression of the transcription factor
Foxp3 (22), a hallmark of regulatory T-cell (Treg) identity and
function (23–25). This suggests that Hh pathway activation by
SAG21k might stimulate Foxp3 expression in the setting of co-
litis. However, as colitis itself causes an increase in colonic Tregs
(26), we were concerned that the suppression of DSS-induced
colitis by SAG21k treatment might confound any SAG21k-
induced augmentation of Foxp3 expression. To address this issue,
we initially examined the effects of DSS and SAG21k treatments
on Foxp3+ Treg levels independently. We first examined the
expression of Foxp3 during acute colitis and found that Foxp3
expression indeed increased in a large proportion of CD4+ T
cells (Fig. 4 A–C), with a corresponding increase in the frequency
of Foxp3+ CD4+ T cells within total cells of the colon (Fig. 4F;
D0 vs. D10 DSS Veh). We also found that Foxp3 expression in
CD4+ T cells increased within 1 d of SAG21k treatment, and
continued throughout our 10-d testing period (Fig. 4 A, D, and
E). However, when SAG21k treatment was combined with a 10-d
DSS injury protocol, the population of Tregs in the colon was
significantly reduced (Fig. 4F; D10 DSS Veh vs. D10 DSS
SAG21k). The SAG21k treatment effect of reducing colitis se-
verity and the accompanying reduction in Tregs thus prevails
over the Treg-inducing effect of SAG21k treatment in the ab-
sence of injury.
To determine whether SAG21k could increase Treg cell levels
in the setting of DSS injury independent of its effects on colitis
severity, we examined the effects of SAG21k during the early
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Fig. 5. Hh response reduces tumor burden in colitis-associated cancer. (A) Overview of AOM–DSS tumor induction studies. Colored bars indicate duration of
exposure to DSS and Hh modulators, A denotes azoxymethane, T indicates days of tamoxifen treatment, and arrowheads indicate day of colon harvest.
(B) Colons from Ptch1+/+ (n = 7) and Ptch1+/− mice (n = 7). Distal colons are oriented toward the Top. (C) Ptch1+/− mice develop reduced overall volume of
colon tumors compared with Ptch1+/+ controls. Each data point represents the total tumor volume. (D) Ptch1+/− mice develop fewer discrete colon tumor foci
than Ptch1+/+ controls. (E) Colons from FVB mice given vismodegib (n = 6), vehicle (n = 7), or SAG21k (n = 7). Similar to XL-139, vismodegib causes a strong
suppression of Hh response (Fig. S2C). Distal colons are oriented toward the Bottom. (F) The vismodegib group shows dramatically increased tumor volumes
compared with vehicle (242.0 vs. 25.1 mm3, respectively; P = 0.0004), whereas the SAG21k group displays decreased tumor volumes (4.2 vs. 25.1 mm3, re-
spectively; P = 0.0168). (G) Fewer discrete tumor foci are present in the SAG21k vs. vehicle group, whereas in the vismodegib group the tumors were too large
to distinguish and count. (H) Colons from GliCreER/+;Smofl/fl (n = 6) and Gli1CreER/+;Smoflox/+ (n = 6). Distal colons are oriented toward the Bottom. (I) Two weeks
after completion of DSS injury, just before administration of tamoxifen (week 4), minimal or no colitis was detected in either GliCreER/+;Smofl/fl or Gli1CreER/+;
Smoflox/+ groups. There was no significant difference in mean colitis severity scores. (J) GliCreER/+;Smofl/fl mice develop an increased overall volume of colon
tumors compared with Gli1CreER/+;Smoflox/+ mice (P = 0.0093).
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phase of DSS injury before the onset of severe colitis and after
only 1 d of SAG21k treatment. After 3 d of DSS exposure, mice
were given either vehicle or SAG21k for 1 d (two doses), and
Treg populations were analyzed at day 4 (Fig. 4A, bottom
schema). Mice given either vehicle or SAG21k did not display
differences in histologic colitis severity from each other or from
day 3 control mice (Fig. 4G). However, Foxp3 expression in-
creased in a significant proportion of CD4+ T cells (Fig. 4H),
with a corresponding increase in the frequency of Foxp3+ CD4+
T cells within total cells of the colon (Fig. 4I). These results
suggest that an early and rapid increase in Treg cells in the colon
may be a mechanism by which SAG21k prevents onset or sup-
presses progression of colitis.
Hh Pathway Activity Reduces Tumor Burden in Colitis-Associated
Colon Cancer. Given that colitis is a well-known risk factor for
human colon cancer (27), we also explored the possibility that
Hh pathway manipulation might also affect the extent of colitis-
associated colon cancer. For our studies we used an established
colitis-dependent murine cancer model [azoxymethane (AOM)–
DSS] in which systemic exposure to the carcinogen AOM is
followed 1 wk later by a week of exposure to DSS (28). First, we
observed that genetic elevation of Hh response in Ptch+/− mice
resulted in a reduced overall tumor burden compared with
Ptch1+/+ littermate controls (Fig. 5 A–D). We then confirmed
and extended these initial findings by pharmacologic manipula-
tion of Hh response during the period of acute colitis in wild-type
FVB mice (Fig. 5A). Pathway suppression using the small-mol-
ecule Hh antagonist vismodegib resulted in significantly greater
tumor burden, whereas pathway elevation using SAG21k resul-
ted in decreased tumor burden (Fig. 5 E and F). These results
are consistent with our observations that Hh pathway activity
decreases colitis severity, and further suggest that decreased
severity of colitis is protective against formation of colon tumors
in the AOM–DSS model.
Finally, we determined whether Hh pathway manipulation
outside of the period of acute colitis can influence colon tumor
growth. We found that reduction of Hh response by tamoxifen-
induced genetic ablation of Smo in GliCreER/+;Smofl/fl mice, with
tamoxifen administration initiated 2 wk after the end of DSS
treatment and after the resolution of acute colitis, resulted in
greater overall tumor burden compared with Gli1CreER/+;Smoflox/+
controls (Fig. 5 A and H–J). These results suggest that stromal Hh
pathway response also reduces colon tumor growth, independent
of its effects on colitis severity.
Discussion
The development of effective interventions for inflammation
hinges on an understanding of its cellular coordinators. Here, we
show that homeostatic suppression of inflammation in the co-
lon is mediated by Hh-responding stromal cells. During DSS-
induced colitis, Hh pathway activity is significantly reduced, and
we show that pharmacologic Hh activation by SAG21k ameliorates
the severity of colitis as well as progression to colitis-associated
adenocarcinoma. We show that Hh activity up-regulates the
expression of IL-10 mRNA in sorted Gli1+ colonic stromal cells
and that the protective effect of Hh activity is largely dependent
on IL-10. Indeed, IL-10 has long been known as an antiin-
flammatory cytokine and a genetic determinant of human and
murine IBD (1, 2).
Previous studies have attributed the protective effect of IL-10
expression in colitis to increased expression in Treg cells of
Foxp3 (22), a transcription factor required for Treg cell function
(23–25). Consistent with such a protective mechanism, we noted
in our DSS model that Hh pathway activation by SAG21k
treatment increased the relative number of Foxp3+CD4+ Treg
cells in the colon, both in a noninjured state as well as in the setting
of early colitis. These previous studies identified CD11b+F4/80+
macrophages, cells of hematopoietic origin, as a major source of
IL-10 that promotes Foxp3 expression (22). Our results here
show that nonhematopoietic Hh-responsive stromal cells also
can contribute to the IL-10–mediated protective effect and, in
fact, that loss of Hh pathway response in these stromal cells
renders animals significantly more vulnerable to DSS-induced
colitis. We also noted a residual but significant protective effect of
SAG21k in IL-10 mutant mice, suggesting that Hh pathway ac-
tivity may also protect against colitis through IL-10–independent
mechanisms. Consistent with such a possibility, a Hh-induced
antiinflammatory program of gene expression in the small in-
testine that did not include induction of IL-10 was previously
reported (29).
Additionally, we have demonstrated that stromal genetic or
pharmacologic Hh pathway activation can reduce tumor burden
in the AOM–DSS colon cancer model, as also recently reported
elsewhere (30). Hence, the beneficial effects of Hh-mediated
suppression of inflammation also extend to its downstream se-
quelae, namely progression to adenocarcinoma. Such effects of
stromal Hh pathway activity have also been seen in epithelial
tumor progression in the pancreas and bladder (10, 14, 31).
Finally, our work identifying a Hh-mediated program of in-
flammatory control has important consequences for human pa-
tients receiving systemic Hh antagonists (e.g., vismodegib) for
the treatment of cancer, including locally advanced or metastatic
basal cell carcinoma. In such cases, the antagonist may increase
risk of IBD relapse or cause exacerbation of preexisting disease.
In particular, our studies showed that Hh pathway blockade led
to moderate-to-severe colitis in the presence of mild DSS ex-
posure that alone caused little pathology (Fig. 1). Beyond ex-
acerbation of preexisting disease, it is possible that treatment with
Hh antagonists may actually increase the risk of contracting IBD.
Indeed diarrhea (28% of patients) and weight loss (44% of pa-
tients) are common side effects of long-term systemic vismodegib
treatment (32). Although the underlying cause of these effects was
not reported, our results suggest that development of IBD cer-
tainly should be considered as a possibility. In sum, by identifying
Hh-responding stromal cells as native coordinators of inflammation,
our studies demonstrate the ability of a small-molecule Hh ag-
onist to control colitis in mice, and suggest the potential appli-
cation of such agents to human patients.
Materials and Methods
Mouse Strains. FVB mice were obtained from Charles River. The following
strains were obtained from The Jackson Laboratory: wild-type C57BL/6 (stock
no. 000664), IL-10−/− C57BL/6 mice (1) (stock no. 002251), R26ZsGreen1/ZsGreen1
(33) (stock no. 007906), R26mTmG/mTmG (34) (stock no. 07576), and Smofl/fl (35)
(stock no. 04526). Ptch+/− mice (13) were backcrossed over 10 generations to
an FVB background. Other mouse stains used were as follows: Gli1CreER/CreER
(36) and Gli1LacZ/LacZ (5). The mouse strains were intercrossed to produce the
experimental cohorts. Mice were housed in a specified pathogen-free barrier
facility at the Stanford School of Medicine. All experiments were conducted
under Protocol 14586, approved by the Stanford Institutional Animal Care
and Use Committee. For experiments in which tamoxifen-induced re-
combination was performed, mice were given 4 mg of tamoxifen (Sigma) per
30 g of body weight on 3 consecutive days by oral gavage. Tamoxifen was
formulated as a 40 mg/mL solution in corn oil. Marking of Gli1+ cells was
accomplished by tamoxifen treatment of Gli1CreER/+;R26ZsGreen1/+ mice to ac-
tivate CreER and induce ZsGreen1 expression, or by tamoxifen treatment of
Gli1CreER/+;R26mTmG/+mice to activate CreER and induce a switch in expression
of the mTmG bifluorescent reporter from mTomato to mGFP (34, 37).
DSS Colitis Studies. Solutions of DSS (MP Biomedicals; average molecular
weight of 36,000–50,000) were made in sterile deionized water at the percent
(weight/volume) concentrations indicated. DSS solutions were substituted for
the regular drinking water at the indicated periods. All mice were between 9
and 16 wk of age at the start of each DSS injury experiment.
SAG21k was formulated as a fine suspension in PBS at a concentration
of 0.05 mg/mL. SAG21k was administered to mice by i.p. injection at a dose of
0.5 mg/kg, given every 12 h. For vehicle controls, PBS was given on the same
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dosing schedule. Both SAG21k and vehicle were administered in a volume of
10 μL per g of mouse weight. The duration of the dosing is described in each
figure. XL-139 was formulated in sterile deionized water at a concentration
of 10 mg/mL and administered to mice by oral gavage every 72 h at a dose of
100 mg/kg. Dosing volume for XL-139 or vehicle (sterile deionized water)
was 10 μL per g of mouse weight.
Colitis severity scores were assessed in a blinded fashion by a single pa-
thologist (E.S.S.) according to a previously described scoring system (38).
AOM–DSS Studies. AOM (Sigma) was formulated in PBS at a concentration of
1 mg/mL. Mice received a single i.p. injection of AOM at a dose of 10 mg/kg at
the start of each tumor induction study, as indicated.
Vismodegib was formulated in a 10 mg/mL suspension in MCT (0.5%
methylcellulose, 0.2% Tween 80). Vismodegibwas given by oral gavage every
12 h at a dose of 100 mg/kg, during the time frame indicated in Fig. 5A.
SAG21k was formulated and administered as described in the section above.
The duration of treatment is indicated in Fig. 5A. Vehicle-treated animals
received PBS injections twice daily as described above.
For tumor measurements, whole colons were dissected from killed ani-
mals. The colons were flushed internally with 10 mL of PBS with a blunt 20-
gauge needle to removes feces. The colons were then cut open longitudinally
and fixed in 4% paraformaldehyde/PBS [4% (wt/vol) PFA/PBS] overnight at
4 °C. To calculate the volume of each colon tumor focus, the maximal length,
width, and height measurements were obtained using digital electronic
calipers. Volume was calculated as an ellipsoid: π/6 × (L ×W × H). The volume
of each focus was summed together for the total tumor volume per colon
per animal.
Immunohistochemistry. Freshly dissected colons were flushed internally with
PBS with a blunt 20-gauge needle as described above. The colons were then
flushed with 4% PFA/PBS to promote accelerated fixation of tissue adjacent
to the lumen. Sections from the distal third of the colon were fixed overnight
in 4% PFA/PBS at 4 °C. A portion of the fixed colon was submitted for
paraffin embedding, sectioning, and H&E staining (Histotec) for histologic
colitis severity assessment. For frozen sections, the fixed tissues were placed
in 30% (wt/vol) sucrose/PBS for 12–24 h overnight at 4 °C. Afterward, the
tissues were embedded into Optimal Cutting Temperature medium
(Sakura Finetek).
Immunofluorescence staining was performed on 7-μm-thick fixed-frozen
colon samples. Permeabilization was performed with 0.5% Triton X-100/PBS
for 15 min. Blocking was performed in 10% (vol/vol) normal goat serum
(NGS)/PBS for 30 min. Primary antibody incubations were performed in 5%
(vol/vol) NGS/PBS for either 2 h at room temperature or overnight at 4 °C.
Secondary antibody incubations were performed in 5% (vol/vol) NGS/PBS. All
washes were performed with 0.1% Tween 20/PBS (PBST). Slides were
mounted with Prolong Gold with DAPI (Invitrogen).
Primary antibodies were as follows: chicken anti–β-galactosidase poly-
clonal (ab616; 1:1,000; Abcam); rabbit anti-GFP polyclonal (1:1,000; Novus);
rat anti-mouse Epcam (clone G8.8; Developmental Studies Hybridoma Bank,
University of Iowa; 1:400 of concentrated supernatant); Alexa Fluor 647 anti-
mouse CD45 (clone 30F-11; 1:200; Biolegend); Alexa Fluor 647 anti-mouse
CD11b (clone M1/70; 1:200; Biolegend); Alexa Fluor 647 anti-mouse CD11c
(clone N418; 1:200; Biolegend); Alexa Fluor 647 anti-mouse F4/80 (clone
BM8; 1:200; Biolegend); Alexa Fluor 647 anti-mouse CD206 (clone C068C2;
1:200; Biolegend); and rabbit anti-mouse CD31 polyclonal (ab28364; 1:100,
Abcam). Secondary antibodies used for visualization were from Sigma or
Jackson ImmunoResearch. Confocal microscopy was performed on Zeiss
LSM 700. Images were processed with ImageJ and Adobe Photoshop CS4
software.
X-gal stains on fresh frozen colon tissue sections (10-μm thickness) were
performed as described previously (37).
FACS. Freshly dissected murine colons were gently flushed with cold calcium
andmagnesium-free PBS (CMF-PBS) using a blunt 20-gauge needle to remove
fecal material, then cut longitudinally, and then pulse vortexed several times
in CMF-PBS to remove adherent debris. The tissue was then transferred to a
tissue culture dish and sliced into 1- to 2-mm3 pieces with a razor blade. Tissue
fragments were subsequently washed in a 25- or 50-mL pipette by aspirating
fragments in CMF-PBS up into the pipette and allowing them to settle by
gravity. Tissue fragments were next digested in 10 mL of digestion buffer
per colon at 37 °C in 5% (vol/vol) CO2 and 20% (vol/vol) O2, for 3–4 h,
pipetting every 15 min. Digestion buffer consisted of advanced Dulbecco’s
modified Eagle medium/F12 (Invitrogen), 1× Glutamax (Invitrogen), 120 μg/mL
penicillin, 100 μg/mL streptomycin, 0.25 μg/mL amphotericin-B, 10 mM
Hepes, 10% (vol/vol) heat-inactivated FCS, with 400 U/mL Collagenase type III
(Worthington), and 100 U/mL DNase I (Worthington). The digestion was mon-
itored under a fluorescence dissection microscope to ensure that the tissue was
adequately dissociated into a single-cell suspension and that fluorescent cells, if
present, were released. At this point, an equal volume of PBS plus 10 mM EDTA
was added for 10 min to help disaggregate remaining clusters of cells. The cell
suspension was then filtered with a 40-μm nylon mesh filter (BD Biosciences),
counted in a hemocytometer, and resuspended at ∼1 × 106 cells per mL in cold
digestion media lacking collagenase and DNase.
Cells in staining buffer were stained in the dark on ice for 20 min with
titered fluorescently conjugated antibodies. Fluorophores varied by experi-
ment. Antibodies included the following: Epcam–allophycocyanin–cyanine 7
or Alexa 647 or Alexa 488 (clone G8.8), CD45–phycoerythrin–Cy5 or Pacific
Blue (clone 30F-11), CD4–allophycocyanin (clone RM4-5), Foxp3 (clone FJK-
16s). Stainings were done with single-color controls, fluorescence-minus-one
(FMO) controls, and fluorescently labeled isotype controls stained at the
same antibody concentration to ensure proper compensation and gating as
well as specificity of antibody binding. Intracellular staining of Foxp3 was
performed using the FOXP3 Fix/Perm Buffer Set (Biolegend). After staining,
cells were washed in cold CMF-PBS, pelleted, and resuspended in cold di-
gestion media lacking collagenase, but including DNase I at 100 U/mL.
After staining, flow cytometry was immediately performed with a 100 μM
nozzle on a BD FACSAria II using FACSDiva software. Debris and doublets
were excluded by sequential gating on forward-scatter area vs. side-scatter
area, followed by forward-scatter width vs. forward-scatter height, followed
by side-scatter height vs. side-scatter width area. Live cells were identified by
exclusion of 4′,6-diamidino-2-phenylindole (Molecular Probes) using FMO
controls. The compensation matrix was calculated with the FACSDiva soft-
ware, and was then checked manually and adjusted as necessary using sin-
gle-color controls. Subpopulations within the live-cell fraction were
identified and gated using isotype controls. To ensure the highest possible
sorting purity, cells of interest were sorted on “single-cell” purity mode into
cold digestion media lacking collagenase and DNase, and purity was then
checked to ensure >95% purity. For some experiments, cells were sorted
directly into TRIzol-LS (Invitrogen) to maximize RNA quality. In those cases, a
test sort into cold digestion media without DNase or collagenase was per-
formed before and after the sort into TRIzol-LS to ensure that cells sorted
into TRIzol-LS were of sufficiently high purity.
Microarrays. Microarray analysis was performed by the Stanford Protein and
Nucleic Acid Facility using GeneChip Mouse Genome 430 2.0 arrays (Affy-
metrix). For microarray experiments, RNA was reverse transcribed to cDNA
with random hexamers and oligo-dT primers and T7 linkers were then added,
followed by two rounds of (linear) T7-mediated amplification. RNA and cDNA
quality was checked with a bioanalyzer. Microarray data were analyzed using
R and Bioconductor. Raw data were normalized with the MAS5 algorithm
using Custom Chip Definition Files that map to Entrez gene identifiers
(Brainarray, version 19; brainarray.mbni.med.umich.edu/Brainarray/Database/
CustomCDF/CDF_download.asp). Differentially expressed genes were identi-
fied using the Student t test.
qRT-PCR. To perform qRT-PCR on whole-colon samples, freshly dissected
colons were first flushed with PBS using a 20-gauge blunt needle. Material
from the distal third of the colon was homogenized in TRIzol Reagent
(Invitrogen) using a hand-held motorized tissue homogenizer. RNA was
purified using the PureLink Mini Kit (Invitrogen). The SuperScript III First-
Strand Synthesis Supermix (Invitrogen) was used to prepare cDNA using
random hexamers. Quantitative pPCR was performed with a Bio-Rad iCycler
using the iQ SYBR Green Supermix (Bio-Rad).
To perform qRT-PCR on cell populations isolated by FACS, the RNA was
purified from TRIzol-LS lysates using the PureLink Micro Kit (Invitrogen) and
eluted in distilled deionized DEPC-treated RNase-free water. For experiments
where more than 10,000 cells were sorted per population, the RNA was
reverse transcribed with random hexamers and oligo-dT primers and then
cDNA was tested directly with quantitative PCR using TaqMan assays (Invi-
trogen) on an ABI7900HT Thermocycler (Applied Biosystems) or designed
primer pairs and SYBR Green on a Bio-Rad iCycler. Samples were loaded in
triplicate on all thermal cycler runs.
For experiments where less than 10,000 cells were sorted, the RNA was
reverse-transcribed and preamplified (12–20 cycles) with gene-specific pri-
mers as described (39) using the Cells-Direct kit (Invitrogen). Briefly, 1.5 μL of
RNA was added to a mixture of 5 μL of CellsDirect 2× buffer, 0.1 μL of
SuperaseIn, 1 μL of SuperScript III RT/Platinum Taq enzyme mix, and 2.5 μL
of a mixture of pooled primer pairs (TaqMan assays) with each assay at 0.2× .
Reverse transcription was performed by incubating at 50 °C for 30 min,
followed by preamplification with cycles of 95 °C for 2 min followed by 60 °C
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for 4 min. The preamplified cDNA was then diluted 1:5 in water. qRT-PCR (40
cycles) was subsequently conducted on diluted preamplified cDNA using
TaqMan assays. If there was no detection of transcript, the result was veri-
fied by two additional RT-PCR experiments. TaqMan assays used included
the following: Actb Mm00607939_s1; Gapdh Mm99999915_g1; Hprt1
Mm01545399_m1; Gli1 Mm00494645_m1 and Mm00494654_m1; Gli2
Mm01293116_m1; Ptch1 Mm01306905_m1; Hhip Mm00469580_m1; and IL10
Mm00439614_m1. Primers used with SYBR Green were as follows: mouse Gli1
(forward, CCAAGCCAACTTTATGTCAGGG; reverse, AGCCCGCTTCTTTGTTAA-
TTTGA); mouse HPRT1 (forward, TCAGTCAACGGGGGACATAAA; reverse,
GGGGCTGTACTGCTTAACCAG); mouse Ptch1 (forward, GCTACGACTATGTC-
TCTCACATCAACT; reverse, GGCGACACTTTGATGAACCA); mouse Hhip (for-
ward, TGAAGATGCTCTCGTTTAAGCTG; reverse, CCACCACACAGGATCTCTCC);
mouse IL-10 (forward, GCTCTTACTGACTGGCATGAG; reverse, CGCAGCTC-
TAGGAGCATGTG); mouse Ihh (forward, GTTCACTGGTACCCTCAGATGCTCTA;
reverse, GTTAGAGTCCCTTCAGCTTCCTGC).
Luminex Assay. Freshly dissected colons (distal third of the colon) were flushed
with PBS as described above to remove feces. Theywere then homogenized in
RIPA buffer [10mMTris (pH 8.0), 140mMNaCl, 1mmEDTA, 0.5mMEGTA, 1%
Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS] using a hand-held
motorized homogenizer. The volume of RIPA buffer was >20-fold more than
the volume of the sample. The RIPA buffer contained 1 tablet of cOmplete
Mini protease inhibitor mixture (Roche) per 10 mL of buffer. The lysate was
incubated at 4 °C for 30 min, followed by centrifugation at 21,000 × g for 15 min
at 4 °C. The clarified supernatant was analyzed by Luminex Assay at the Stan-
ford Human Immune Monitoring Center.
Statistical Analyses. Graphing and statistical analyses were performed with
GraphPad Prism 6 software. SEmeasurements are presented for all quantified
data, unless otherwise specified. Group comparisons were performed with a
two-tailed Student t test. Kaplan–Meier analyses were performed with the
log-rank test.
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